Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.
Zacks
More News
CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio, while B of A cuts Lumentum's target.read more...
Benzinga
Why Is Belite Bio Stock Gaining Monday?
Belite Bio (BLTE) stock jumps 3% on positive Phase 3 DRAGON trial data for its Stargardt disease drug candidate tinlarebant.read more...
Benzinga
Full Transcript: Belite Bio Q1 2026 Earnings Call
read more...
Benzinga
Belite Bio Enters Oversold Territory (BLTE)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
Belite Bio (BLTE) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Nathan Mata Sells 1,000 Shares of Belite Bio (NASDAQ:BLTE) Stock
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Nathan Mata sold 1,000 shares of Belite Bio stock in a transaction on Tuesday, May 5th. The stock was sold at an average price...
MarketBeat
Belite Bio (BLTE) Projected to Post Quarterly Earnings on Tuesday
Belite Bio (NASDAQ:BLTE) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-belite-bio-inc-stock...
MarketBeat
Insider Selling: Belite Bio (NASDAQ:BLTE) Insider Sells 1,000 Shares of Stock
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Nathan Mata sold 1,000 shares of the firm's stock in a transaction on Wednesday, April 29th. The shares were sold at an average...
MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the firm...
MarketBeat

Advertisement|Remove ads.